NCT00864201Unknown3 期
A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output∕cardiac input (CO∕CI), mean right arterial pressure (mRAP)
研究概览
简要总结
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women ≥ 18 years of age
- •For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using one of the following methods of contraception:
- •Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination with a spermicide. A double-barrier method is recommended.
- •Intrauterine devices (IUDs)
- •Oral contraceptives, if used in combination with a barrier method
- •Body weight of 40 kg or higher
- •Patients diagnosed with connective tissue disease
- •Hemodynamics at rest, based on cardiac catheterization, should be as follows:
- •Mean pulmonary arterial pressure (mPAP) : 18 - 25 mmHg
- •PCWP ≤ 15 mmHg
- •Hemodynamics during exercise, based on cardiac catheterization, should be as follows: mPAP > 30 mmHg
- •Provide written informed consent
排除标准
- •PAH associated with any other condition
- •Severe obstructive lung disease : FEV1∕ FVC <0.5
- •Total lung capacity <60% of normal predicted value
- •Unable or unwilling have a cardiac catheterization procedure
- •Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (6-MWT)
- •Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
- •Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
- •AST and ∕or ALT > 3 times uln
- •Hemoglobin concentration > 25% below the lower limit of normal
- •Systolic blood pressure < 85 mm Hg
- •Pregnancy or breast-feeding
- •Treatment or planned treatment with another investigational drug
- •Treatment with an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion
- •Treatment with calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) within 1 week of study start;
- •Known hypersensitivity to bosentan or any of the excipients
研究组 & 干预措施
bosentan
Experimental
干预措施: bosentan (Drug)
结局指标
主要结局
The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output∕cardiac input (CO∕CI), mean right arterial pressure (mRAP)
时间窗: 6 months
次要结局
- Change in hemodynamics at rest: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output/cardiac input (CO∕CI), mean right arterial pressure (mRAP)(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic SclerosisScleroderma, SystemicNCT02480335University Medical Center Groningen20
已完成
2 期
Effect of Bosentan on Endothelial Function in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT01357109Karolinska Institutet56
进行中（未招募）
不适用
Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACProgressive pulmonary sarcoidosisMedDRA version: 9.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosisEUCTR2007-005117-18-ATMedical University of Vienna, Department of Clinical Pharmacology
已完成
4 期
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyNCT00317486Actelion54
已完成
1 期
Influence of Bosentan on the Pharmacokinetics of NintedanibHealthyNCT02667704Boehringer Ingelheim13